Immunic, Inc. (IMUX) stock
IMUXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.99−0.40 (-5.41%)
Close on Nov 20, 2026Market cap $95.37MP/E –Yield 0.00%
Immunic free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Immunic's free cash flow for the twelve months ending Jun 30, 2026 was -$88.05M. For fiscal 2025 it was -$85.97M. The highest annual figure on record is -$9.51M in fiscal 2012.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$85.97M | – |
| FY2024 | Dec 31, 2024 | -$85.03M | – |
| FY2023 | Dec 31, 2023 | -$71.16M | – |
| FY2022 | Dec 31, 2022 | -$65.26M | – |
| FY2021 | Dec 31, 2021 | -$83.30M | – |
| FY2020 | Dec 31, 2020 | -$46.27M | – |
| FY2019 | Dec 31, 2019 | -$28.60M | – |
| FY2018 | Dec 31, 2018 | -$9.77M | – |
| FY2017 | Dec 31, 2017 | -$41.08M | – |
| FY2016 | Dec 31, 2016 | -$36.33M | – |
| FY2015 | Dec 31, 2015 | -$52.29M | – |
| FY2014 | Dec 31, 2014 | -$42.23M | – |
| FY2013 | Dec 31, 2013 | -$30.13M | – |
| FY2012 | Dec 31, 2012 | -$9.51M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$31.25M | – |
| Q1 FY2026 | Mar 31, 2026 | -$17.30M | – |
| Q4 FY2025 | Dec 31, 2025 | -$19.29M | – |
| Q3 FY2025 | Sep 30, 2025 | -$20.21M | – |
| Q2 FY2025 | Jun 30, 2025 | -$24.65M | – |
| Q1 FY2025 | Mar 31, 2025 | -$21.82M | – |
| Q4 FY2024 | Dec 31, 2024 | -$22.97M | – |
| Q3 FY2024 | Sep 30, 2024 | -$20.85M | – |
| Q2 FY2024 | Jun 30, 2024 | -$17.22M | – |
| Q1 FY2024 | Mar 31, 2024 | -$24.00M | – |
| Q4 FY2023 | Dec 31, 2023 | -$14.19M | – |
| Q3 FY2023 | Sep 30, 2023 | -$17.36M | – |
| Q2 FY2023 | Jun 30, 2023 | -$20.00M | – |
| Q1 FY2023 | Mar 31, 2023 | -$19.62M | – |
| Q4 FY2022 | Dec 31, 2022 | -$15.10M | – |
| Q3 FY2022 | Sep 30, 2022 | -$13.67M | – |
| Q2 FY2022 | Jun 30, 2022 | -$15.79M | – |
| Q1 FY2022 | Mar 31, 2022 | -$20.69M | – |
| Q4 FY2021 | Dec 31, 2021 | -$23.70M | – |
| Q3 FY2021 | Sep 30, 2021 | -$17.62M | – |
| Q2 FY2021 | Jun 30, 2021 | -$29.02M | – |
| Q1 FY2021 | Mar 31, 2021 | -$12.96M | – |
| Q4 FY2020 | Dec 31, 2020 | -$13.99M | – |
| Q3 FY2020 | Sep 30, 2020 | -$11.97M | – |
| Q2 FY2020 | Jun 30, 2020 | -$9.28M | – |
| Q1 FY2020 | Mar 31, 2020 | -$11.03M | – |
| Q4 FY2019 | Dec 31, 2019 | -$6.29M | – |
| Q3 FY2019 | Sep 30, 2019 | -$5.99M | – |
| Q2 FY2019 | Jun 30, 2019 | -$11.00M | -222.1% |
| Q1 FY2019 | Mar 31, 2019 | -$5.32M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.47M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.09M | – |
| Q2 FY2018 | Jun 30, 2018 | $9.01M | – |
| Q1 FY2018 | Mar 31, 2018 | -$13.22M | – |
| Q4 FY2017 | Dec 31, 2017 | -$10.03M | – |
| Q3 FY2017 | Sep 30, 2017 | -$9.59M | – |
| Q2 FY2017 | Jun 30, 2017 | -$10.28M | – |
| Q1 FY2017 | Mar 31, 2017 | -$11.18M | – |
| Q4 FY2016 | Dec 31, 2016 | -$9.22M | – |
| Q3 FY2016 | Sep 30, 2016 | -$8.16M | – |
See a number that looks wrong?